Global Interactive Technologies (NASDAQ:GITS) and Simulations Plus (NASDAQ:SLP) Critical Comparison

Global Interactive Technologies (NASDAQ:GITS) and Simulations Plus (NASDAQ:SLP) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Global Interactive Technologies and Simulations Plus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Interactive Technologies	N/A	-104.68%	-93.94%
Simulations Plus	-81.66%	14.02%	13.09%

Insider and Institutional Ownership

0.2% of Global Interactive Technologies shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 9.3% of Global Interactive Technologies shares are held by company insiders. Comparatively, 19.1% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Global Interactive Technologies and Simulations Plus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Interactive Technologies	1	0	0	0	1.00
Simulations Plus	1	6	3	0	2.20

Simulations Plus has a consensus target price of $25.00, suggesting a potential upside of 100.96%. Given Simulations Plus’ stronger consensus rating and higher possible upside, analysts clearly believe Simulations Plus is more favorable than Global Interactive Technologies.

Earnings & Valuation

This table compares Global Interactive Technologies and Simulations Plus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Interactive Technologies	$790,000.00	11.47	-$6.17 million	($0.59)	-4.19
Simulations Plus	$79.18 million	3.17	-$64.72 million	($3.20)	-3.89

Global Interactive Technologies has higher earnings, but lower revenue than Simulations Plus. Global Interactive Technologies is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Global Interactive Technologies has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Simulations Plus has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Summary

Simulations Plus beats Global Interactive Technologies on 10 of the 14 factors compared between the two stocks.

About Global Interactive Technologies

Global Interactive Technologies, Inc. engages in the provision of a global multi-media platform for users to interact with other like-minded users to share appreciation of various types of entertainment and cultures such as K-POP and modern Korean culture. It operates through the FANTOO platform. The company was founded on October 20, 2021 and is headquartered in Seoul, South Korea.

About Simulations Plus

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.